Ocugen Inc.

04/29/2024 | Press release | Distributed by Public on 04/29/2024 04:46

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024